Discussions with leaders: *JNM*’s series of interviews with leaders in nuclear and molecular imaging and therapy continues with a conversation with David Collingridge, editor-in-chief of *The Lancet Oncology* and publishing director of *The Lancet* specialty journals.  

The future of theranostics: Solones and colleagues provide an overview of already approved theranostic agents and those in development and discuss the potential impacts on cancer and on the field of nuclear medicine.  

**Page 311**

**18**F-**FDG** or **bacteria-targeting** tracers? Chen and Dilsizian offer an educational overview of 18F-FDG PET/CT and contrast CT imaging for use as markers to assess early response and predict outcomes in oropharyngeal squamous cell carcinoma.  

**Page 319**

PET/CT and tumor progression in OPSCC: Wu and colleagues describe development of quantitative imaging features on 18F-FDG PET and contrast CT imaging to determine whether 18F-choline PET/CT can improve the specificity of multiparametric MRI of the prostate in patients with Gleason \( \geq 3+4 \) prostate cancer.  

**Page 337**

Interobserver agreement in 18F-**NaF** PET/CT: Zacho and colleagues evaluate interobserver agreement on patient lesion levels for 18F-sodium fluoride PET/CT detection of bone metastases in patients with prostate cancer.  

**Page 344**

First-line **90**Y for uveal melanoma: Ponti and colleagues explore the safety and efficacy of 90Y selective internal radiation therapy as first-line therapy in patients with uveal melanoma metastatic to the liver.  

**Page 350**

**18**F-**Fluoroglutamine** dynamic PET: Grkovski and colleagues investigate the pharmacokinetic properties of this radiotracer for imaging tumor glutamine flux and metabolism properties in patients with cancer.  

**Page 357**

**18**F-**DOPA** PET/CT and neuroblastoma: Picard and colleagues evaluate the diagnostic role of 18F-DOPA PET/CT at the time of staging in children with neuroblastoma, its ability to assess treatment response, and its prognostic value.  

**Page 367**

AUC for differentiated thyroid: Donohoe and members of a cross-disciplinary work group present new appropriate use criteria for nuclear medicine in the evaluation and treatment of differentiated thyroid cancer.  

**Page 375**

Patient release after 131I therapy: Wu and colleagues report on results from a nationwide survey to evaluate whether practices regarding hospital release of differentiated thyroid cancer patients treated with 131I have changed since publication of NRC Regulatory Issue Summary 2011-01.  

**Page 397**

Total-body **PSMA** PET for bone staging: Pomykala and colleagues determine the relationship between serum prostate-specific antigen levels and the incidence of bone metastases detected by total-body 68Ga-prostate-specific membrane antigen-11 PET/CT and assess the effect of expanding the imaging field.  

**Page 405**

End-of-treatment **PET** in TB: Lawal and colleagues explore the impact of findings on end-of-treatment 18F-FDG PET/CT on tuberculosis relapse in patients treated with a standard regimen of antituberculous treatment for drug-sensitive pulmonary tuberculosis.  

**Page 412**

PET and inferior colliculi: Spec and colleagues use 18F-FDG PET to evaluate the glucose metabolism of the inferior colliculus and primary auditory cortex in patients with asymmetric hearing loss.  

**Page 418**

**18**F-**ASEM** PET in MCI: Coughlin and colleagues use this tracer to examine the relationship between the \( \alpha7 \)-nicotinic acetylcholine receptor and Alzheimer disease in elderly controls and in patients with mild cognitive impairment.  

**Page 423**

**64**Cu-ATSM as a redox imaging marker: Flobeg and colleagues demonstrate that this 64Cu-labeled PET tracer, developed for hypoxia imaging, is dependent on cellular redox state, with or without hypoxia.  

**Page 427**

**89**Zr-HDL tracer guides CSF1R therapy: Mason and colleagues propose an 89Zr-labeled high-density lipoprotein nanotracer as a means of rapidly monitoring response to immunotherapy targeting tumor-associated macrophages.  

**Page 433**

**CDK4/6** inhibitor for **PET**: Ramos and colleagues detail development of an 13C-labeled cyclin-dependent kinase 4/6 inhibitor for breast cancer imaging.  

**Page 437**

Tumor-residualizing GRPR-targeted agents: Zhang and colleagues present a strategy using irreversible inhibitors of cysteine cathepsins as trapping agents to increase tumor retention of agonistic and antagonistic pharmacophores targeting the gastrin-releasing peptide receptor.  

**Page 443**

Thirty-day total-body PET: Rosenkranz and Cai provide perspective on the recent completion of development of total-body PET scanners and discuss a related article in this issue of *JNM*.  

**Page 451**

30-day **89**Zr-antibody PET: Berg and colleagues investigate the technical feasibility and utility of the mini-EXPLORER PET for total-body imaging of 89Zr-labeled antibodies in rhesus monkeys up to 30 days after injection.  

**Page 453**

Preclinical PET/CT standardized protocols: McDougall and colleagues assess the variability of current preclinical PET/CT acquisition/reconstruction protocols across multiple centers and propose protocols for standardization of multicenter data for routine scanning in preclinical PET/CT laboratories.  

**Page 461**

Multivendor, multicenter radiomic study: Pfau and colleagues detail the impact of harmonized image reconstruction on feature consistency, using 3D printed phantom inserts reflecting realistic tumor shapes and heterogeneity uptake.  

**Page 469**